Over 80% of patients with Alzheimer’s disease (AD) develop ‘noncognitive’ neuropsychiatric symptoms at some point during the course of their illness. Depression is among the most frequent of such comorbidities. Affecting up to 50% of AD patients, depression is associated with severe negative consequences for patients and caregivers. Despite having a presentation in the context of AD that differs from typical ‘geriatric’ depression, it can be detected and quantified reliably, and can be differentiated from the other neuropsychiatric symptoms of AD. Several effective treatment modalities for depression in AD are available. In many cases, these reduce its adverse impact on patients and caregivers. This paper provides an overview of current knowledge regarding depression in AD for the clinician. It is followed by a practical discussion of the detection, evaluation, quantification, differential diagnosis and treatment of depression in AD.

Keywords:
Dementia, Depression, Alzheimer’s disease
This content is only available via PDF.
© 2004 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.